Abstracts tagged "Biomarkers"

Abstract Number: 0884 • ACR Convergence 2023
Identification of a Mast Cell-high Synovial Pathotype of Osteoarthritis
Shady Younis, Audrey Bai, heidi Wong, Zelda Love, Qian Wang and William Robinson, Stanford School of Medicine, Stanford, CA
Background/Purpose: Mast cells in the osteoarthritis (OA) synovium correlate with disease severity. This study aimed to further elucidate the role of mast cells in OA…
Abstract Number: 1184 • ACR Convergence 2023
A Wearable-Sensor for Assessment of Gait and Chair Stand Patterns in People with Knee Osteoarthritis: Validation and Responsiveness to Treatment of a Potential Digital Biomarker
Deepak Kumar¹, Lukas Adamowicz², Benjamin Senderling¹, Mary Gheller¹, Michael LaValley³, Kathryn Bacon¹, Pirinka Georgiev², Charmaine Demanuele², Paul Wacnik² and Tuhina Neogi⁴, ¹Boston University, Boston, MA, ²Pfizer Inc., Cambridge, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Boston University School of Medicine, Boston, MA
Background/Purpose: The objectives of this study in people with knee osteoarthritis (OA) were to (a) examine the agreement between measures of gait and chair stand…
Abstract Number: 1489 • ACR Convergence 2023
Treatment with Upadacitinib in Patients with Systemic Lupus Erythematosus Results in the Inhibition of B-Cell–related Biomarkers: Analysis of the M19-130 (SLEek) Phase 2 Study
Marie-Claude Gaudreau¹, James Fann¹, Alan Friedman¹, Thierry Sornasse¹ and Joan Merrill², ¹AbbVie, Inc., North Chicago, IL, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: B-cell hyperactivity (1) is a hallmark of the disordered immunity of SLE, arising in the context of a complex array of innate and adaptive…
Abstract Number: 1716 • ACR Convergence 2023
High-Throughput Semi-Automated Micro-CT Analysis Identifies the Cuboid Bone as a Sex-Dependent Biomarker of Inflammatory-Erosive Arthritis in TNF-Tg Mice
H. Mark Kenney¹, Kiana Chen², Lindsay Schnur³, Jeffrey Fox³, Ronald Wood³, Lianping Xing⁴, Christopher T Ritchlin⁵, Homaira Rahimi⁶, Edward Schwarz⁶ and Hani Awad³, ¹University of Rochester School of Medicine and Dentistry, Henrietta, NY, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³University of Rochester Medical Center, Rochester, NY, ⁴University of Rochester Medical Center, Webster, NY, ⁵University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY, ⁶University of Rochester, Rochester, NY
Background/Purpose: Development of reliable disease activity biomarkers is critical for diagnostics, prognostics, and novel drug development. In the case of preclinical models of inflammatory-erosive arthritis,…
Abstract Number: 1984 • ACR Convergence 2023
Therapeutic Effects of Pentosan Polysulfate Sodium on Clinical and Disease Modifying Outcomes in Subjects with Knee Osteoarthritis
Mukesh Ahuja¹, Donna Skerrett², Curtis Gravance³, Divya Navuru⁴, Ravi Krishnan⁵, Charles Inderjeeth⁶, Philip Bloom⁷ and Schnitzer Thomas⁸, ¹Paradigm Biopharmaceuticals, Oak Brook, IL, ²Paradigm Biopharmaceuticals, New York, NY, ³Paradigm Biopharmaceuticals, Melba, ID, ⁴Paradigm Biopharmaceuticals, Melbourne, Australia, ⁵Paradigm Biopharmaceuticals, Adelaide, Australia, ⁶University of Western Australia / Linear Clinical Research, Perth, Australia, ⁷Sportsmed Biologic, Melbourne, Australia, ⁸Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Osteoarthritis (OA) is an inflammatory joint disease, causing chronic pain, disability, and reduced quality of life. Affected joints may include the knee, hip, and…
Abstract Number: 2342 • ACR Convergence 2023
Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial
Aida Santos da Costa¹, Thomas Dörner², Andrea Grioni¹, Alexandre Avrameas¹, Ulrike Sommer¹, Rainer Hillenbrand¹, Valeria De Luca¹, Enrico Ferrero¹, Andre Nogueira da Costa¹, Isabelle Isnardi¹ and Stephen J Oliver¹, ¹Novartis Pharma AG, Basel, Switzerland, ²Department of Medicine, Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum, Berlin, Germany
Background/Purpose: Ianalumab (VAY736) is an afucosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
Abstract Number: 2393 • ACR Convergence 2023
CXCL9/IL-6 and MMP3/CD141 Ratio Allow to Discriminate Between Isolated PMR and GCA/PMR Overlap
andre ramon¹, helene Greigert², adrien guilloteau³, claudie cladière⁴, marion ciudad⁵, Sylvain Audia⁶, paul ornetti⁷, jean-Francis Maillefert⁷, Bernard Bonnotte² and Maxime Samson², ¹Department of Rheumatology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Methodological Support Unit (USMR), Dijon-Bourgogne University Hospital, Dijon, France, ⁴INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Bourgogne Franche-Comté University, Dijon, France, ⁵INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France, ⁶Department of Internal Medicine and Clinical Immunology, Dijon-Bourgogne University Hospital, Dijon, France, ⁷Department of Rheumatology , Dijon-Bourgogne University Hospital, Dijon, France
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are frequently overlapping conditions. It is estimated that 16 to 21% of PMR patients have GCA.…
Abstract Number: 0179 • ACR Convergence 2023
Social Disparities and Pathology Markers at Lupus Nephritis Diagnosis Predict Worse Kidney Outcomes
Shivani Garg¹, Brad Astor², Amish Raval², S. Sam Lim³, Weixiong Zhong², Sarah Panzer², Brad Rovin⁴ and Christie M. Bartels², ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, WI, ³Emory University, Atlanta, GA, ⁴Ohio State University, Columbus, OH
Background/Purpose: At diagnosis, a typical 30-year-old with lupus nephritis (LN) already has 10-fold higher chronic kidney disease (CKD) risk than peers and LN is a…
Abstract Number: 0558 • ACR Convergence 2023
Elevated Serum Levels of S100A8/A9 Discriminate Systemic Lupus Erythematosus Patients with Cognitive Impairment from Patients Without Impairment
Carolina Munoz-Grajales¹, Michelle Barraclough², Juan Pablo Diaz Martinez³, Jiandong Su², Kathleen Bingham², Mahta Kakvan⁴, Roberta Kretzmann⁵, Carmela Tartaglia⁶, Lesley Ruttan⁷, May Choi⁸, Simone Appenzeller⁹, Sherief Marzouk⁵, Dennisse Bonilla², Patti Katz¹⁰, Dorcas Beaton¹¹, Robin Green⁵, Joan Wither² and Zahi Touma⁵, ¹UHN/TWH, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹UNICAMP, Campinas, Brazil, ¹⁰University of California San Francisco, San Rafael, CA, ¹¹Institute for Work & Health, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Studies have reported that SLE patients with different…
Abstract Number: 0708 • ACR Convergence 2023
NFKB1 and NFKBIA: Relevant Players in the Pathogenesis of IgA Vasculitis?
Joao Carlos Batista-Liz¹, Verónica Pulito-Cueto¹, María Sebastián Mora-Gil¹, Belén Sevilla-Pérez², María Teresa Leonardo³, Norberto Ortego-Centeno⁴, Ana Peñalba³, Javier Narvaez⁵, luis martin penagos⁶, Emilio Rodrigo⁶, Lara Belmar-Vega⁶, Cristina Gomez-Fernandez⁷, Luis Caminal-Montero⁸, Paz Collado⁹, Miren Uriarte-Ecenarro¹⁰, Esther Vicente Rabaneda¹¹, Esteban Rubio¹², Manuel León Luque¹², Juan María Blanco-Madrigal¹³, Eva Galindez-Agirregoikoa¹⁴, Santos Castañeda¹⁵, Miguel A Gonzalez-Gay¹⁶, Ricardo Blanco¹⁷ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ³Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Medicine Department, Universidad de Granada, Granada, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Division of Nephrology, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-DIVAL, Santander, Spain, ⁷Division of Dermatology,Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁸Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, ⁹Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, ¹⁰Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ¹¹Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹²Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹³Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ¹⁴Basurto University Hospital, Bilbao, Spain, ¹⁵Hospital Universitario de la Princesa, Madrid, Spain, ¹⁶IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Immunoglobulin A Vasculitis (IgAV) is a B-cell-mediated inflammatory disease. NF-kappa B (NF-kB) plays a key role in autoimmunity and inflammation1. In this regard, the…
Abstract Number: 0899 • ACR Convergence 2023
Complement Factor I (CFI) Gene Expression by Kidney Tubular Cells Is Increased in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
Shudan Wang¹, John Greally², Masako Suzuki³, Jee-Young Moon², Tao Wang², Yvonne M Saenger², Brad Rovin⁴ and J. Michelle Kahlenberg⁵, ¹Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Texas A&M University, College Station, TX, ⁴Ohio State University, Columbus, OH, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Tubulointerstitial injury is a strong predictor of progression to kidney failure in lupus nephritis (LN). Prior animal studies suggest intrarenal complement activation has an…
Abstract Number: 1194 • ACR Convergence 2023
Extent of Subregional Involvement of Subchondral Bone Marrow Lesions in Incident Knee OA Is Associated with Weight-Bearing Knee Pain
Kent Kwoh¹, Frank Roemer², Erin Ashbeck³ and Ali Guermazi⁴, ¹University of Arizona, Tucson, AZ, ²Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany, ³University of Arizona Arthritis Center, Tucson, AZ, ⁴Boston University, Boston, MA
Background/Purpose: Subchondral bone marrow lesions (BMLs) have been associated with incident and progressive pain and reported to fluctuate along with concurrent fluctuations in symptoms. While…
Abstract Number: 1492 • ACR Convergence 2023
Pre-treatment Differentially Expressed Metagenes Characterize Systemic Lupus Patients Who Subsequently Achieve Clinical Response to Belimumab
Miles Smith¹, Kevin Thomas¹, Nicolas Dominguez¹, Susan Macwana¹, Wade DeJager¹, Stan Kamp¹, Carla Guthridge¹, Bridget Parrish¹, Cristina Arriens², Judith James¹, Joan Merrill¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK
Background/Purpose: Belimumab, which targets the B Cell activator and survival factor BLyS, is an approved treatment for systemic lupus (SLE) and has demonstrated efficacy in…
Abstract Number: 1733 • ACR Convergence 2023
Platelet-Derived Growth Factor Is a Mediator of Disease in an Animal Model of Rheumatoid-Associated Interstitial Lung Disease
Nozima Aripova¹, Michael Duryee¹, Amy Nelson¹, Carlos Hunter¹, Breanna Butler¹, Bryant England¹, Jill Poole¹, Geoffrey Thiele¹ and Ted R Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a leading cause of mortality in RA with limited treatment options as well as lack of available…
Abstract Number: 2095 • ACR Convergence 2023
Integrated Analysis of Gene Expression and Methylation Identifies Biomarkers Associated with Mode of Action of Upadacitinib Treatment in Rheumatoid Arthritis
Preeti Lal¹, Yilin Xu¹, Thierry Sornasse¹, Rhiya Sharma¹, Laleh Jafarpour¹, Heidi Camp¹ and Iain McInnes², ¹AbbVie, Inc., North Chicago, IL, ²University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA), an oral Janus kinase (JAK) inhibitor, significantly improves the signs and symptoms of RA patients1-3. The present study aims to elucidate the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].